Back to Search Start Over

Inhibition of human amylin aggregation by Flavonoid Chrysin: An in-silico and in-vitro approach.

Authors :
Alkahtane AA
Alghamdi HA
Almutairi B
Khan MM
Hasnain MS
Abdel-Daim MM
Alghamdi WM
Alkahtani S
Source :
International journal of medical sciences [Int J Med Sci] 2021 Jan 01; Vol. 18 (1), pp. 199-206. Date of Electronic Publication: 2021 Jan 01 (Print Publication: 2021).
Publication Year :
2021

Abstract

Islet amyloid polypeptide (amylin), consecrated by the pancreatic β-cells with insulin, has a significant role to play in maintaining homeostasis of islet cell hormones. Alzheimer's disease is the predominant source of dementia. However, its etiology remains uncertain; it appears that type 2 diabetes mellitus and other prediabetic states of insulin resistance contribute to the intermittent Alzheimer's disease presence. Amylin is abnormally elevated in Type II diabetes patients, accumulated into amylin aggregates, and ultimately causes apoptosis of the β-cells, and till date, its mechanism remains unclear. Several flavonoids have inhibitory effects on amylin amyloidosis, but its inhibition mechanisms are unknown. Screening a collection of traditional compounds revealed the flavone Chrysin, a potential lead compound. Chrysin inhibits amyloid aggregate formation according to Thioflavin T binding, turbidimetry assay. We report results of molecular interaction analysis of Chrysin with amylin which shows potent binding affinity against amylin. Pharmacokinetics and Drug likeness studies of Chrysin also suggest that it is a potential lead compound. Therefore, Chrysin prevented amylin aggregation.<br />Competing Interests: Competing Interests: The authors have declared that no competing interest exists.<br /> (© The author(s).)

Details

Language :
English
ISSN :
1449-1907
Volume :
18
Issue :
1
Database :
MEDLINE
Journal :
International journal of medical sciences
Publication Type :
Academic Journal
Accession number :
33390788
Full Text :
https://doi.org/10.7150/ijms.51382